FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246978541> ?p ?o ?g. }

• W4246978541 endingPage "4003" @default.
• W4246978541 startingPage "4003" @default.
• W4246978541 abstract "4003 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to doxorubicin plus sorafenib (D+S) showed a significant improvement in overall survival favoring D+S (JAMA, 2011). The results appeared promising compared to the historic outcomes seen in the pivotal sorafenib (S) trials. CALGB 80802 was designed to determine if D+S improved survival compared to S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were randomized to receive D 60 mg/m2 every 21 days plus S 400 mg PO twice daily (D+S) or S alone. For bilirubin ≥ 1.3x normal, D and S doses were halved. D was maxed out at 360 mg/m2. The study was stratified by extent of disease (locally advanced; metastatic), the primary endpoint was overall survival (OS); and secondary endpoint progression-free survival (PFS). The final analysis was to occur when 364 events were observed among 480 total patients, with 90% power to detect a 37% increase in median OS (10.7 to 14.7 months; 1-sided α = 0.05). Results: The Alliance DSMB halted the study after accrual of 346 patients (173 on each of D+S and S) when a futility boundary was crossed at a planned interim analysis. With 107 events in each arm, median OS was 9.3 months (95%CI 7.1-12.9) for D+S, and 10.5 months (95% CI 7.4-14.3) for S with a hazard ratio (HR) 1.06 (95% CI 0.8- 1.4) for D+S vs. S. Median PFS was 3.6 (95% CI 2.8-4.6) and 3.2 months (95% CI 2.3-4.1), respectively (HR = 0.90, 95% CI 0.72-1.2). There were 38 deaths on treatment: 18 on D+S and 20 on S. Among these 8 [sepsis (1), dysphagia (1), pneumonia (1), cardiac (2), hepatic failure (2), and not otherwise specified (1)] on D+S, and 3 [fatigue (1), hepatic failure (1), and a secondary malignancy (1)] on S, were at least possibly related to treatment. A maximum grade 3 or 4 only hematologic adverse events (AE) occurred in 37.8% of patients on D+S and 8.1% of patients on S. Non-hematologic AEs were comparable, in 63.6% and 61.5% of patients, respectively. Conclusions: The addition of D to S resulted in higher toxicity and did not improve OS or PFS. The S median OS of about 10 months is consistent with previous reports. NCI Grant U10CA180821 Clinical trial information: NCT01015833." @default.
• W4246978541 created "2022-05-12" @default.
• W4246978541 creator A5001637416 @default.
• W4246978541 creator A5005234747 @default.
• W4246978541 creator A5007197290 @default.
• W4246978541 creator A5010372361 @default.
• W4246978541 creator A5011233983 @default.
• W4246978541 creator A5012785119 @default.
• W4246978541 creator A5017709484 @default.
• W4246978541 creator A5019481117 @default.
• W4246978541 creator A5037875642 @default.
• W4246978541 creator A5045543523 @default.
• W4246978541 creator A5045618241 @default.
• W4246978541 creator A5047736184 @default.
• W4246978541 creator A5050288292 @default.
• W4246978541 creator A5058825770 @default.
• W4246978541 creator A5065435809 @default.
• W4246978541 creator A5068644454 @default.
• W4246978541 creator A5074891676 @default.
• W4246978541 creator A5077630534 @default.
• W4246978541 creator A5080776657 @default.
• W4246978541 creator A5081273660 @default.
• W4246978541 date "2016-05-20" @default.
• W4246978541 modified "2023-10-18" @default.
• W4246978541 title "Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)." @default.
• W4246978541 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.4003" @default.
• W4246978541 hasPublicationYear "2016" @default.
• W4246978541 type Work @default.
• W4246978541 citedByCount "10" @default.
• W4246978541 countsByYear W42469785412017 @default.
• W4246978541 countsByYear W42469785412018 @default.
• W4246978541 countsByYear W42469785412019 @default.
• W4246978541 countsByYear W42469785412020 @default.
• W4246978541 countsByYear W42469785412021 @default.
• W4246978541 crossrefType "journal-article" @default.
• W4246978541 hasAuthorship W4246978541A5001637416 @default.
• W4246978541 hasAuthorship W4246978541A5005234747 @default.
• W4246978541 hasAuthorship W4246978541A5007197290 @default.
• W4246978541 hasAuthorship W4246978541A5010372361 @default.
• W4246978541 hasAuthorship W4246978541A5011233983 @default.
• W4246978541 hasAuthorship W4246978541A5012785119 @default.
• W4246978541 hasAuthorship W4246978541A5017709484 @default.
• W4246978541 hasAuthorship W4246978541A5019481117 @default.
• W4246978541 hasAuthorship W4246978541A5037875642 @default.
• W4246978541 hasAuthorship W4246978541A5045543523 @default.
• W4246978541 hasAuthorship W4246978541A5045618241 @default.
• W4246978541 hasAuthorship W4246978541A5047736184 @default.
• W4246978541 hasAuthorship W4246978541A5050288292 @default.
• W4246978541 hasAuthorship W4246978541A5058825770 @default.
• W4246978541 hasAuthorship W4246978541A5065435809 @default.
• W4246978541 hasAuthorship W4246978541A5068644454 @default.
• W4246978541 hasAuthorship W4246978541A5074891676 @default.
• W4246978541 hasAuthorship W4246978541A5077630534 @default.
• W4246978541 hasAuthorship W4246978541A5080776657 @default.
• W4246978541 hasAuthorship W4246978541A5081273660 @default.
• W4246978541 hasConcept C126322002 @default.
• W4246978541 hasConcept C141071460 @default.
• W4246978541 hasConcept C143998085 @default.
• W4246978541 hasConcept C168563851 @default.
• W4246978541 hasConcept C203092338 @default.
• W4246978541 hasConcept C207103383 @default.
• W4246978541 hasConcept C2776694085 @default.
• W4246978541 hasConcept C2778019345 @default.
• W4246978541 hasConcept C2778695046 @default.
• W4246978541 hasConcept C31760486 @default.
• W4246978541 hasConcept C44249647 @default.
• W4246978541 hasConcept C61943457 @default.
• W4246978541 hasConcept C71924100 @default.
• W4246978541 hasConcept C90924648 @default.
• W4246978541 hasConceptScore W4246978541C126322002 @default.
• W4246978541 hasConceptScore W4246978541C141071460 @default.
• W4246978541 hasConceptScore W4246978541C143998085 @default.
• W4246978541 hasConceptScore W4246978541C168563851 @default.
• W4246978541 hasConceptScore W4246978541C203092338 @default.
• W4246978541 hasConceptScore W4246978541C207103383 @default.
• W4246978541 hasConceptScore W4246978541C2776694085 @default.
• W4246978541 hasConceptScore W4246978541C2778019345 @default.
• W4246978541 hasConceptScore W4246978541C2778695046 @default.
• W4246978541 hasConceptScore W4246978541C31760486 @default.
• W4246978541 hasConceptScore W4246978541C44249647 @default.
• W4246978541 hasConceptScore W4246978541C61943457 @default.
• W4246978541 hasConceptScore W4246978541C71924100 @default.
• W4246978541 hasConceptScore W4246978541C90924648 @default.
• W4246978541 hasIssue "15_suppl" @default.
• W4246978541 hasLocation W42469785411 @default.
• W4246978541 hasOpenAccess W4246978541 @default.
• W4246978541 hasPrimaryLocation W42469785411 @default.
• W4246978541 hasRelatedWork W2082648967 @default.
• W4246978541 hasRelatedWork W2495512985 @default.
• W4246978541 hasRelatedWork W2562916117 @default.
• W4246978541 hasRelatedWork W2754556903 @default.
• W4246978541 hasRelatedWork W2957827266 @default.
• W4246978541 hasRelatedWork W3029083233 @default.
• W4246978541 hasRelatedWork W3192121286 @default.
• W4246978541 hasRelatedWork W4232617294 @default.
• W4246978541 hasRelatedWork W4323536446 @default.
• W4246978541 hasRelatedWork W4379336131 @default.
• W4246978541 hasVolume "34" @default.

• next